{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "MEHTSOP056 Monitoring (Trust Sponsored) 1.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 15,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "RESEARCH & DEVELOPMENT MONITORING (TRUST SPONSORED)"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "MEHTSOP056"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP)"
                    },
                    {
                        "text": "SOP"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "All staff"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "th12 December 2019"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "th11 December 2022"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "Service Development"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "17"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Research & Development"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Lauren Perkins, R & D Manager"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\uf0fcMEHT \u25a1 BTUH \u25a1 SUH"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "Research and Development"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "01/07/2019"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Tracey Camburn R & D Director, Clinical Lead Nurse"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "26/07/2019"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "DRAG Chair's Action"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "12th December 2019"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group"
                    },
                    {
                        "text": "Date: December 2019"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "Intranet & Website"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 3,
            "data": {
                "url": "MEHTSOP056 Monitoring (Trust Sponsored) 1.0.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 13,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Consulted With:"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Mandy Austin"
                    },
                    {
                        "text": "R&D Coordinator"
                    },
                    {
                        "text": "01/07/2019"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "MEHTSOP003 SAEs (Sponsored) MEHTSOP005 Informed Consent MEHTSOP062 Trial Master File (Sponsored) MEHTSOP061 Research Staff Training SOP-07- Role of CI, pharmacy, nuclear medicine and R&D MEHTSOP059 Amendments MEHTSOP043 Serious Breaches (Sponsored) MEHTSOP057 Sponsor Oversight MEHTSOP055 Research Applications MEHTSOP051 DSURs (Sponsored) MEHTSOP050 Archiving of Essential Documents MEHTSOP046 Study Closure MEHTSOP044 Management of Source Data"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 10,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Newly created"
                    },
                    {
                        "text": "12th December 2019"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 7,
            "data": {
                "is_heading": 1,
                "text": "Contents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Background"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Purpose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Applicable"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Procedure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "Equality Impact Assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 0,
                "text": "Appendix 1 - Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 0,
                "text": "Appendix 2 \u2013 Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "BACKGROUND"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "This document sets out the roles, responsibilities and procedures to be followed by Mid Essex Hospital Services NHS Trust (MEHT) staff who are involved in the monitoring of research studies."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 0,
                "prefix": 1.2,
                "text": "It provides guidance on the monitoring process, including the procedure to be followed prior to, during and after a monitoring visit."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "PURPOSE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "Monitoring is an integral process in the Quality Control (QC) of sponsored research projects and is the act of overseeing the progress of the clinical trial, and of ensuring that it is conducted, recorded, and reported in accordance with the protocol, applicable SOPs & policies, GCP, and the applicable regulatory requirement(s)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 0,
                "prefix": 2.2,
                "text": "The purpose of monitoring is to ensure that the safety, welfare and rights of the human subject is maintained and the reported trial data is accurate, complete and verifiable from the source documentation. Implementation of monitoring procedures as a QC process ensures that where inherent risks associated with the trial IMP(s), vulnerabilities of the protocol design, ongoing trial conduct and risk-benefit profile of the IMP are identified, that effective approaches to mitigate these risks and resolve issues which may impact upon the human subject's safety and/or integrity of trial data can be effectively implemented and overseen by the Sponsor."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 0,
                "prefix": 2.3,
                "text": "Monitoring is part of a multi-factorial approach to ensuring the quality of research for all Sponsored research projects."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 1,
                "prefix": 2.4,
                "text": "Extent & Scope of Monitoring"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 0,
                "text": "2.4.1 The Sponsor will determine the extent and nature of monitoring required for each sponsored research project which should be documented in the trial specific monitoring plan."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 25,
            "data": {
                "is_heading": 0,
                "text": "2.4.2 The content of the monitoring plan should be based upon the findings of the Sponsor's risk assessment. The Sponsor's risk assessment will identify the core risks inherent in the trial protocol, which impact upon participant safety and rights, and the reliability of the results."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 26,
            "data": {
                "is_heading": 0,
                "text": "2.4.3 The risk categorisation of the trial will be based upon the marketing status of the IMP and the standard medical care, which in turn will determine the necessary trial procedures for monitoring the safety of the trial participants. In addition the risk assessment will also identify the potential vulnerabilities in the trial design and methodology."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 0,
                "text": "2.4.4 A combination of analysis of the inherent risk of the IMP, trial design and methodology in addition to other risk factors (assessment of trial site(s) (where applicable), facilities, experience and training needs of study staff) will determine"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 0,
                "text": "the focus and intensity of monitoring activity to be performed and the level of management and organisational oversight required for the trial (see also gSOP10)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 29,
            "data": {
                "is_heading": 0,
                "text": "2.4.5 For all Sponsored CTIMPs a combination of monitoring methods may be employed which should be trial specific and documented in the monitoring plan and/or trial protocol.These may include;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 0,
                "text": "\u25cf On site Monitoring"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Central Monitoring of Trial conduct and data and monitoring activity through the use of meetings/ teleconferences and telephone calls which do not require on site monitoring (see section 5.4)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 1,
                "prefix": 2.5,
                "text": "Trial Specific Monitoring plan development and Appointment of the Clinical Trial Monitor"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 0,
                "text": "2.5.1 The Completion of this document should involve a multidisciplinary approach and involve the Chief Investigator (CI) or delegated individual."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 0,
                "text": "2.5.2 The completed risk assessment and associated monitoring plan will form the basis of common understanding by all the stakeholders (Sponsor, Investigators, regulators, funders, research governance staff, pharmacy) on the risk of that trial and facilitate a risk proportionate approach to the monitoring of the trial."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 0,
                "text": "2.5.3 The extent of safety and data monitoring to be employed for a trial will have implications for the funding and resources required, and as a result it is recommended that consideration for the extent and scope of monitoring to be employed is made during the initial application and protocol development stage for all Sponsored CTIMPs."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 0,
                "text": "2.5.4 The monitoring plan should be approved by the Research and Development (R&D) Co-director and submitted to the MHRA alongside the CTA authorisation application during the set-up of the trial (if applicable). The final Monitoring plan should receive approval by the R&D Co-director."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 0,
                "text": "2.5.5 The trial risk assessment should be revisited periodically over the life cycle of the trial to take into account new information and emergent unanticipated risks that have become apparent after the start of the trial. These may require modification(s) to the extent and nature of monitoring being implemented which require subsequent adaptation to the trial monitoring plan. These changes should be approved by the Sponsor and provided to the MHRA (if applicable) for information only."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 38,
            "data": {
                "is_heading": 0,
                "text": "2.5.6 The appointment of the trial monitor and designated monitoring responsibilities should be documented in the trial specific monitoring plan. Monitoring activity, however, may be delegated to specific research team members (e.g. trial coordinator, medical monitor, trial manager, data manager) Monitoring responsibilities and applicable personnel should be documented in the monitoring plan."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "APPLICABLE TO"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "Any Trust employee (including those with an honorary research contract or letter of access) involved with Clinical research including Chief Investigators, Principal Investigators, Consultants, Clinical Trial Pharmacists, Research Managers, Research Nurses, Research Midwives, Allied Health Professionals, Trial Coordinators and Data Managers."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "RESPONSIBILITIES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 42,
            "data": {
                "is_heading": 1,
                "prefix": 4.1,
                "text": "The Sponsor should ensure that;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 43,
            "data": {
                "is_heading": 0,
                "text": "4.1.1 Each trust Sponsored project has undergone a risk assessment and provided approval for the risk adapted monitoring plan."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 0,
                "text": "4.1.2 There is a standard set of requirements for the management and oversight to both single centre and multi centre CTIMPs that ensures appropriate levels of both local management and organisational oversight."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 0,
                "text": "4.1.3 The clinical trial monitor/delegated individual is appropriately qualified and trained in order to have the scientific and/or clinical knowledge to monitor the trial adequately."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 0,
                "text": "4.1.4 Potential Serious Breaches of GCP and/or the study protocol identified through routine on site and/or central monitoring or through oversight committee meetings are reviewed through the trust's R&D department in order to determine the appropriate approach to take with respect to corrective action(s), expedited reporting and implementation of preventative measure(s)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 1,
                "prefix": 4.2,
                "text": "The CI (or delegated individual) should ensure that;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 48,
            "data": {
                "is_heading": 0,
                "text": "4.2.1 The trial risk assessment form is completed as part of the application process. This should involve identifying and considering the main hazards inherent in the clinical trial protocol and risks associated with the IMP and other intervention(s) being tested."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 0,
                "text": "4.2.2 The appropriate oversight committee structure is incorporated into the design of the trial protocol at the time of the initial submission to R&D for review by the R&D department (gSOP-10)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 50,
            "data": {
                "is_heading": 0,
                "text": "4.2.3 Where a Sponsored research studies has been initiated at a participating site(s) the trial site has the adequate qualifications, resources and facilities, including laboratories, equipment and staff, to safely and properly conduct the trial and that these remain adequate throughout the study period."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 0,
                "text": "4.2.4 Each participating site on a multicentre research study undergoes a formal initiation prior to activation to recruit trial participants and is routinely monitored throughout the lifecycle of the trial utilising monitoring methods identified and described in the trial monitoring plan."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 0,
                "text": "4.2.5 Potential Serious Breaches of GCP and/or the study protocol identified through routine on site and/or central monitoring or through oversight committee meetings are reviewed by the R&D department in order to determine the appropriate approach to take with respect to corrective action(s), expedited reporting and implementation of preventative measure(s)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 1,
                "prefix": 4.3,
                "text": "The Clinical Trials Pharmacist should ensure that;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 0,
                "text": "4.3.1 The trial specific pharmacy pack is completed and approved by the R&D department for all multi-centre trials."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "text": "4.3.2 Potential Serious Breaches of GCP and/or the study protocol identified through routine on site and/or central monitoring or through oversight committee meetings are reviewed through the trust's RDAG in order to determine the appropriate approach to take with respect to corrective action(s), expedited reporting and implementation of preventative measure(s)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 0,
                "text": "4.3.3 The R&D manager and/or delegated trial team individual(s) appointed monitoring responsibilities for the Sponsored research study should ensure that;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 0,
                "text": "a) A trial specific monitoring plan is developed and approved by the R&D department."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 58,
            "data": {
                "is_heading": 0,
                "text": "b) An initiation visit is conducted for all Single Centre research studies, and where the trial is being initiated at participating sites, an initiation visit/meeting is completed by the delegated member of the trial coordinating team (see gSOP 17)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 0,
                "text": "c) Interim monitoring visits are conducted for single centre research studies and at a frequency and intensity specified in the trial monitoring plan. For multi-centre research studies the allocated monitor should oversee the specified monitoring processes for the participating site(s) which are performed by the designated member of the trial team."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 0,
                "text": "d) A close monitoring visit is performed for all single centre research studies. For multi-centre research studies the allocated monitor should oversee the specified monitoring processes for the participating site(s) which are performed by the designated member of the trial team."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 61,
            "data": {
                "is_heading": 0,
                "text": "e) Potential Serious Breaches of GCP and/or the study protocol identified through routine on site and/or central monitoring or through oversight committee meetings are reviewed through the R&D department in order to determine the appropriate approach to take with respect to corrective action(s), expedited reporting and implementation of preventative measure(s)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "PROCEDURES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 63,
            "data": {
                "is_heading": 1,
                "text": "Monitoring visit pattern"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 1,
                "prefix": 5.1,
                "text": "Single Centre trials"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 0,
                "text": "5.1.1 In all cases the Monitor or delegated individual should conduct a study initiation visit/ pre activation meeting and a close out visit. Interim monitoring visits should be conducted at a frequency specified in the study monitoring plan."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 0,
                "text": "5.1.2 All single centre trials should be set up to ensure that the appropriate oversight structure is established."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 67,
            "data": {
                "is_heading": 1,
                "prefix": 5.2,
                "text": "Multi-centre trials"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 68,
            "data": {
                "is_heading": 0,
                "text": "5.2.1 The procedures for monitoring participating sites will be based on the risk adapted monitoring approach specified in the study specific monitoring plan. Participating sites may be subject to a combination of central and/ or on site monitoring depending on the outcome of the risk assessment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 69,
            "data": {
                "is_heading": 0,
                "text": "5.2.2 Where multi-centre sites have not been specified to require on site monitoring, a triggered on site visit should be performed under the following circumstances;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 0,
                "text": "a) Quality concerns at site following central monitoring checks"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 71,
            "data": {
                "is_heading": 0,
                "text": "b) Clinical Trial Regulations Compliance Self Completion Checklist."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 72,
            "data": {
                "is_heading": 0,
                "text": "c) Identification of a potential risk to the trial."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 73,
            "data": {
                "is_heading": 0,
                "text": "d) Investigation into a potential Serious Breach of the trial protocol/ GCP."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 0,
                "text": "e) Other reasons as recommended by the trial site or Sponsor (e.g. site selection for regulatory inspection, provision of trial specific training to the site staff personnel, random selection)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 75,
            "data": {
                "is_heading": 0,
                "text": "5.2.3 Site visits may be performed if emergent risks occur during the course of the trial. The monitoring plan should be amended to reflect the response to these emergent risks."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 76,
            "data": {
                "is_heading": 1,
                "prefix": 5.3,
                "text": "Study Initiation Visit"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 0,
                "text": "5.3.1  A study initiation visit/meeting should take place before recruitment begins at any recruiting site. Procedures for this are outlined in gSOP 17."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 1,
                "prefix": 5.4,
                "text": "Interim on-site Monitoring Visit"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 79,
            "data": {
                "is_heading": 0,
                "text": "5.4.1 The completion of interim on-site monitoring visits is applicable to single centre trials and multi-centre trials where on site monitoring has been identified as a requirement following the study risk assessment. For multicentre trials where on site monitoring is required the responsibility for monitoring may be delegated and should be defined in the monitoring plan. The Sponsor should ensure that the monitor is adequately qualified and trained to perform the monitoring duties pertinent to that trial in such circumstances."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 0,
                "text": "5.4.2 The monitor/designated individual should follow procedures outlined in the monitoring plan and should ensure that the interim monitoring visit report is completed at a frequency defined in the monitoring plan."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 0,
                "text": "5.4.3 If routine interim monitoring visits identify any individual events, or a series of events which may be considered a potential serious Breach of GCP/protocol the monitor/designated individual should ensure that the findings are escalated to the CI/PI and Sponsor as soon as possible after they are identified. The escalation process for reporting potential breaches described in gSOP-10 should be followed."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 1,
                "prefix": 5.5,
                "text": "Central Monitoring and Oversight"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 83,
            "data": {
                "is_heading": 0,
                "text": "5.5.1 The CI/delegated individual should employ a number of different approaches and techniques to monitor the conduct and progress of the trial centrally. This is applicable to both single and multicentre trials."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 84,
            "data": {
                "is_heading": 0,
                "text": "5.5.2 Procedures to be employed for central monitoring should be defined in the monitoring plan. The methods employed may include but should not be limited to the following;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 0,
                "text": "a) Eligibility checks prior to randomisation (where applicable)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 86,
            "data": {
                "is_heading": 0,
                "text": "b) Rates of recruitment, withdrawals and losses to follow up by site"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 87,
            "data": {
                "is_heading": 0,
                "text": "c) Monitoring trial progress from the coordinating centre by the trial team"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 0,
                "text": "d) Resolving trial related issues by telephone/email"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 0,
                "text": "e) Ongoing training/meetings and teleconferences"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 0,
                "text": "f) Documented telephone conversations"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 0,
                "text": "g) Checks for missing or invalid data (range and consistency checks)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 92,
            "data": {
                "is_heading": 0,
                "text": "h) Checks that dose adjustments, investigation and management of events are consistent with the protocol"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 0,
                "text": "i) Calendar checks"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 0,
                "text": "j) Checks for unusual data patterns"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 0,
                "text": "k) Assessment of adverse events and toxicity reporting rates"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 0,
                "text": "l) CRFs completed by authorised persons"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 0,
                "text": "m) Database validation checks"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 0,
                "text": "n) External verification (with participant consent) of events (e.g. birth, disease and death registries)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 99,
            "data": {
                "is_heading": 0,
                "text": "o) Web enabled training"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 100,
            "data": {
                "is_heading": 0,
                "text": "p) Ongoing training/meetings and teleconferences"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 1,
                "prefix": 5.6,
                "text": "Monitoring Calls"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 102,
            "data": {
                "is_heading": 0,
                "text": "5.6.1 Monitoring calls may be undertaken as outlined in the trial protocol"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 1,
                "prefix": 5.7,
                "text": "Trial Oversight Committees"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 104,
            "data": {
                "is_heading": 0,
                "text": "5.7.1 The appropriate level of oversight committee structure should be established during the design of the study protocol and should be proportional to the study design and risk. Procedures for the management of oversight committees and the composition, frequency and structure of committee membership and planned meetings should be detailed in the trial protocol and specified in trial specific monitoring plan (please see gSOP 10)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 105,
            "data": {
                "is_heading": 1,
                "prefix": 5.8,
                "text": "Study close out monitoring procedures"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 106,
            "data": {
                "is_heading": 0,
                "text": "5.8.1 A close out visit should be performed as soon as practical after the \u201clast patient last visit\u201d or following the premature termination of the trial/site and after the specified monitoring activity for the trial has been completed."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 107,
            "data": {
                "is_heading": 0,
                "text": "5.8.2 As part of the close down procedures the monitor/ designated individual should ensure that any corrective actions outstanding from monitoring visits are completed by the study CI/site team and respective pharmacy department as required."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 108,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "EQUALITY IMPACT ASSESSMENT"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 109,
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "Mid Essex Hospital Services NHS Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals. (Refer to Appendix 2)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 110,
            "data": {
                "is_heading": 1,
                "text": "Appendix 1: Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 111,
            "data": {
                "is_heading": 1,
                "text": "Adverse Event (AE) -  Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 112,
            "data": {
                "is_heading": 1,
                "text": "Chief Investigator (CI) -  The person who takes overall responsibility for the design, conduct and reporting of a study if it is at one site; or if the study involves researchers at more than one site, the person who takes primary responsibility for the design conduct and reporting of the study whether or not that person is an Investigator at any particular site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 113,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial of an Investigational Medicinal Product (CTIMP) - This is defined as any Clinical Research Study which intends to generate new information about the safety or efficacy of a Medicinal Product."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 114,
            "data": {
                "is_heading": 1,
                "text": "Data Monitoring Committee (DMC) -  A group of experts (including Clinical experts, Statisticians and if appropriate Ethicists and Patient Advocates) not associated with the trial that monitor safety and efficacy data while a trial is ongoing. The role of the Data Monitoring Committee is to review the accruing trial data and to assess whether there are any safety issues that should be brought to participants attention or any reasons for the trial not to continue. The DMC may comprise of MEHT staff who are independent from the study, but specialists who are independent from MEHT can also be included. As a minimum, an Independent Chair, Statistician and Clinician to the study should be present during DMC meetings."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 115,
            "data": {
                "is_heading": 1,
                "text": "Delegated Individual (DI) - An individual delegated by the PI to carry out their task(s)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 116,
            "data": {
                "is_heading": 1,
                "text": "Good Clinical Practice (GCP) - The principles of Good Clinical Practice in Clinical Trials as set down in Articles 2-5 of the GCP Directive and implemented in the UK by Schedule 1 of the Medicines for Human Use (Clinical Trials) Regulations 2004 (S.I.2004/1031) as amended by S.I. 2006/1928."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 117,
            "data": {
                "is_heading": 0,
                "text": "Good Clinical Practice is a set of internationally recognised ethical and scientific quality requirements which must be observed for designing, conducting, recording and reporting clinical trials that involve the participation of human subjects."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 118,
            "data": {
                "is_heading": 1,
                "text": "Honorary Research Contracts - HRCs are required for researchers who are not employees of the NHS and whose activities could have a foreseeable and direct impact on patient care"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 119,
            "data": {
                "is_heading": 1,
                "text": "International Conference on Harmonisation (ICH) -  International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use is a joint initiative involving both regulators and research-based industry focusing on the technical requirements for medicinal products containing new drugs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 120,
            "data": {
                "is_heading": 1,
                "text": "Letter of Access - Letters of access enable NHS employees or staff with an honorary clinical contract (e.g. clinical academics) with one NHS organisation to conduct research in another NHS organisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 121,
            "data": {
                "is_heading": 1,
                "text": "Principal Investigator (PI) - The leader responsible for a team of individuals conducting a study at a (participating) site"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 122,
            "data": {
                "is_heading": 1,
                "text": "The Medicines & Healthcare products Regulatory Agency (MHRA) - The government agency which is responsible for ensuring that medicines and medical devices work, and are acceptably safe."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 123,
            "data": {
                "is_heading": 0,
                "text": "The MHRA can also be defined as:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 124,
            "data": {
                "is_heading": 0,
                "text": "MHRA (Medicines) is the competent authority for the UK in relation to the EU Directive and the Clinical Trials Regulations. MHRA (Devices) is the competent authority for the UK in relation to the Medical Devices Regulations 2002."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 125,
            "data": {
                "is_heading": 1,
                "prefix": 2004.0,
                "text": "The Regulations - Medicines for Human Use (Clinical Trial) Regulations 2004 transposed the EU Clinical Trials Directive into UK legislation, as Statutory Instrument 2004 no 1031. This became effective on the 1st May  An amendment to implement Directive 2005/28/EC was made to the Regulations as Statutory Instrument 2006 no 1928."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 126,
            "data": {
                "is_heading": 1,
                "text": "Trial Management Group (TMG) - The Trial Management Group for each trial is set up to oversee the clinical and practical aspects of the day to day management of the trial. The TMG  normally  includes  individuals  such  as  the  Chief  Investigator,  Trial Physician(s), Statistician, Trial Coordinator, Research Nurse, and Data Manager(s). The role of the group is to monitor all aspects of the conduct and progress of the trial, ensure that the protocol is adhered to and take appropriate action to safeguard participants and the quality of the trial itself."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 127,
            "data": {
                "is_heading": 0,
                "text": "Research & Development Monitoring (Trust Sponsored) / MEHTSOP056/1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 128,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 129,
            "data": {
                "is_heading": 0,
                "text": "Research & Development Monitoring (Trust Sponsored) / MEHTSOP056/1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 130,
            "data": {
                "is_heading": 1,
                "text": "Appendix 2: Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 131,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Research & Development Monitoring (Trust Sponsored) / MEHTSOP056"
            }
        },
        {
            "type": "table",
            "sequence_num": 132,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "A change in a service to patients"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to an existing policy"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to the way staff work"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A new policy"
                    },
                    {
                        "text": "X"
                    },
                    {
                        "text": "Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "New SOP"
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "Review"
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and clinicians"
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change? b) If so, with whom?"
                    },
                    {
                        "text": "Refer to pages 1 and 2"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 133,
            "data": {
                "is_heading": 1,
                "text": "Preliminary analysis completed by:"
            }
        },
        {
            "type": "table",
            "sequence_num": 134,
            "data": {
                "num_rows": 1,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Research & Development Manager"
                    },
                    {
                        "text": "Date"
                    },
                    {
                        "text": "July 2019"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 135,
            "data": {
                "is_heading": 0,
                "prefix": 13.0,
                "text": ""
            }
        }
    ]
}